Effectiveness of nirsevimab reimmunization against RSV hospitalization during the second season in high-risk children

Summary

Results suggest a moderate effectiveness of reimmunization with a second nirsevimab dose against hospitalization for respiratory syncytial virus infection during the second season in high-risk children, although the estimated effectiveness was highly uncertain (42%; 95% confidence interval: −25% to 73%).